Steven Cohen Design Therapeutics, Inc. Transaction History
Point72 Asset Management, L.P.
- $36.6 Billion
- Q3 2024
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 1,600,740 shares of DSGN stock, worth $10.1 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,600,740
Previous 990,801
61.56%
Holding current value
$10.1 Million
Previous $3.32 Million
159.45%
% of portfolio
0.02%
Previous 0.01%
Shares
6 transactions
Others Institutions Holding DSGN
# of Institutions
102Shares Held
31MCall Options Held
2.3KPut Options Held
16.5K-
Sr One Capital Management, LP6.53MShares$41.1 Million11.88% of portfolio
-
Logos Global Management LP San Francisco, CA4.22MShares$26.5 Million3.0% of portfolio
-
Black Rock Inc. New York, NY2.3MShares$14.5 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.89MShares$11.9 Million0.55% of portfolio
-
Baker Bros. Advisors LP New York, NY1.74MShares$11 Million0.1% of portfolio
About Design Therapeutics, Inc.
- Ticker DSGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,807,900
- Market Cap $351M
- Description
- Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...